More than one-third of adults in the United States are obese. It should come as no surprise that these individuals are at increased risk for cardiovascular disease, diabetes, certain cancers, and other significant comorbidities. If current trends continue, nearly 60% of US adults will be overweight or obese by 2030. New guidelines and pharmacotherapy are available to assist the medical community in its efforts to manage this disease. Experts in obesity share their insights on the latest approaches and treatment options for overweight and obese patients.
Ken Fujioka, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Co., Ltd; Enteromedics, Inc.; Gelesis; Nazura; Novo Nordisk; Zafgen; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Eisai Co., Ltd; Novo Nordisk; Shire; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Eisai Co., Ltd; Enteromedics, Inc.; Orexigen Therapeutics, Inc.; Novo Nordisk; Shire
Timothy Church, MD, MPH, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: VIVUS Inc.
Received grants for clinical research from: VIVUS Inc.; Coca Cola; Orexigen Therapeutics, Inc.; Arena Pharmaceuticals, Inc.
Owns stocks, stocks options, or bonds from: Catapult Health; FIX: Fitness Interactive eXperience Employed by a commercial interest: ACAP Health
Timothy Garvey, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Daiichi Sankyo, Inc.; VIVUS Inc.; Eisai, Inc.; Takeda Pharmaceuticals North America, Inc.; Novo Nordisk; Janssen Pharmaceuticals, Inc.; LipoScience; Boehringer Ingelheim Pharmaceuticals, Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Weight Watchers; Sanofi; Eisai, Inc.
Owns stocks, stocks options, or bonds from: Pfizer, Inc.; Lilly; Merck & Co., Inc.; Isis Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation
Patrick O'Neil, PhD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Eisai Inc.; Novo Nordisk
Received grants for clinical research from: Orexigen Therapeutics, Inc.; Weight Watchers International; Novo Nordisk
Received reimbursement for travel expenses from: VIVUS, Inc.
Donna Ryan, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novo Nordisk; Eisai, Inc.; Takeda Pharmaceuticals North America, Inc.; VIVUS Inc.; Janssen Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Takeda Pharmaceuticals North America, Inc.
Owns stocks, stocks options, or bonds from: Scientific Intake
Participation by Dr Kahan as an advisor does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
Scott Kahan, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Co., Ltd; Novo Nordisk; Takeda Pharmacueticals North America, Inc.; VIVUS Inc.
Received grants for clinical research from: Eisai Co., Ltd; Novo Nordisk; Takeda Pharmacueticals North America, Inc.; VIVUS Inc.
Book Royalties (Other): Johns Hopkins University Press; Lippincott Williams & Wilkins; Wolters-Kluwer